Stock Scorecard
Stock Summary for Atea Pharmaceuticals Inc (AVIR) - $4.65 as of 2/20/2026 7:29:06 PM EST
Total Score
12 out of 30
Safety Score
18 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for AVIR
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for AVIR
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for AVIR
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for AVIR
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for AVIR (18 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 3 |
| Stock Price Trend (Max of 10) | 0 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 1 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 5 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for AVIR
Financial Details for AVIR
Company Overview |
|
|---|---|
| Ticker | AVIR |
| Company Name | Atea Pharmaceuticals Inc |
| Country | USA |
| Description | Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapies for patients suffering from viral infections. The company is headquartered in Boston, Massachusetts. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 3/5/2026 |
Stock Price History |
|
| Last Day Price | 4.65 |
| Price 4 Years Ago | 4.81 |
| Last Day Price Updated | 2/20/2026 7:29:06 PM EST |
| Last Day Volume | 487,510 |
| Average Daily Volume | 516,098 |
| 52-Week High | 4.80 |
| 52-Week Low | 2.46 |
| Last Price to 52 Week Low | 89.02% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 18.63 |
| Sector PE | 148.47 |
| 5-Year Average PE | -0.50 |
| Free Cash Flow Ratio | 4.70 |
| Industry Free Cash Flow Ratio | 12.36 |
| Sector Free Cash Flow Ratio | 31.12 |
| Current Ratio Most Recent Quarter | 16.66 |
| Total Cash Per Share | 0.99 |
| Book Value Per Share Most Recent Quarter | 4.04 |
| Price to Book Ratio | 1.17 |
| Industry Price to Book Ratio | 3.36 |
| Sector Price to Book Ratio | 33.63 |
| Price to Sales Ratio Twelve Trailing Months | 1.90 |
| Industry Price to Sales Ratio Twelve Trailing Months | 47.64 |
| Sector Price to Sales Ratio Twelve Trailing Months | 23.44 |
| Analyst Buy Ratings | 2 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 78,127,000 |
| Market Capitalization | 363,290,550 |
| Institutional Ownership | 78.21% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 264.10% |
| Annual Earnings Growth | -23.85% |
| Reported EPS 12 Trailing Months | -1.77 |
| Reported EPS Past Year | -1.37 |
| Reported EPS Prior Year | -2.00 |
| Net Income Twelve Trailing Months | -147,025,000 |
| Net Income Past Year | -168,385,000 |
| Net Income Prior Year | -135,956,000 |
| Quarterly Revenue Growth YOY | 295.20% |
| 5-Year Revenue Growth | -66.48% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 77,344,000 |
| Total Cash Past Year | 64,696,000 |
| Total Cash Prior Year | 143,823,000 |
| Net Cash Position Most Recent Quarter | 77,344,000 |
| Net Cash Position Past Year | 64,696,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 438,867,000 |
| Total Stockholder Equity Prior Year | 555,192,000 |
| Total Stockholder Equity Most Recent Quarter | 315,780,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -134,205,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -1.72 |
| Free Cash Flow Past Year | -135,499,000 |
| Free Cash Flow Prior Year | -85,395,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.24 |
| MACD Signal | 0.21 |
| 20-Day Bollinger Lower Band | 2.48 |
| 20-Day Bollinger Middle Band | 3.50 |
| 20-Day Bollinger Upper Band | 4.52 |
| Beta | 0.23 |
| RSI | 68.77 |
| 50-Day SMA | 3.27 |
| 150-Day SMA | 3.43 |
| 200-Day SMA | 4.04 |
System |
|
| Modified | 2/20/2026 5:59:57 PM EST |